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Abstract

Introduction

In this double blind study, seven out of fourteen
patients who had received a cementless hydroxyapatitecovered hip prosthesis were given calcitriol (1 p.g daily),
and seven an inert placebo for a period of four months.
At the end of this period, total body bone densitometry
(TBBD) and absorptiometric measurements in the regions of interest (ROis) close to the prosthesis and in the
opposite femur revealed that the TBBD values had decreased in the patients receiving placebo and increased
in those receiving calcitriol. Furthermore, bone mineral
density in the ROis had increased on the non-operated
side of the calcitriol-treated patients (although to a lesser
extent in the calcitriol-treated group).

The lengthening of average life expectancy has led
to an increase in the incidence of fractures of the femoral neck due to osteoporosis and the physiological reduction in bone mineral content. Another increasingly frequent disease is coxarthrosis due to age and increase in
body weight. These pathological conditions often require the implantation of a hip prosthesis. The use of
cementless hip prostheses has naturally reduced the incidence of the biological and mechanical alterations due to
the cement itself [24], but their introduction has also led
to stress shielding and the consequent remodelling of
periprosthetc femoral tissue [1, 19, 20, 38]. This remodelling is caused by various factors, some of which
are related to the prosthesis (its design, the modulus of
elasticity of the material, and the presence and extent of
micro and macroporous surfaces) [18], and others to the
patient (age, body weight, systemic or regional osteoporosis, physical activity and bone ingrowth). Periprosthetc osteoporosis may lead to implant movement but
does not appear to alter the possibility of adequate bone
ingrowth [1, 18]. When a cementless prosthetc implant
in either porotic or normal bone is being considered, the
important factors are the choice of the prosthesis (which
must guarantee sufficient elasticity and ensure an adequate press-fit on the bone), its structural material (titanium) and any coating it may have (such as hydroxyapatite) [1].
Periprosthetc bone loss can be verified by using
conventional radiology [18, 24] and/or densitometry.
The first method provides a morphological description
and allows any implant defects to be evaluated, but it
cannot be used to monitor bone density over time because of its inability to detect bone density variations of
less that 30-40 % [23, 27]. Bone densitometry by means
of dual photon absorptiometry (DPA) or dual X-ray
absorptiometry (DXA) is the most accurate and precise
method for studying bone mass [3, 32, 35, 34], and has
been used in a number of studies to measure periprosthetic bone loss [1, 20, 25, 26, 33, 37]. In these
studies, the periprosthetic areas have been subdivided in
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Figure 1. DXA visual display of proximal femur: location of the four regions of interest.
various ways, the in vivo reproducibility in the studied
regions ranging from 2% to 7% [25, 26, 33, 37, 40).
An accurate and precise evaluation of bone mass density
(BMD) in the regions of interest (ROis) of the limb with
a prosthesis, when compared with those of the contralateral limb, can provide indications concerning local
bone remodelling and predict the success and durability
of the implant [2, 12, 13, 15, 16, 31, 36). Depending
on the time at which the measurements were made and
the analytical techniques used, absorptiometry investigations of periprosthetic regions have documented a
more or less evident demineralization [1, 20, 25, 33).
Kilgus et al. [25] measured bone density in six medial
and six lateral regions around the prosthesis: 5-7 years
after the operation, in comparison with controls, they
found that: (a) there was a reduction in BMD of 20.2%
in the region containing the lesser trochanter, and of
25.5% in the region below it; (b) the greatest reduction
in BMD was in the region above the lesser trochanter

(34.8%); and (c) the reduction in BMD was always less
in the distal regions. Engh et al. [18] measured bone
density post mortem by subdividing the prosthetic part
of the femur into three equal areas and then comparing
them with the corresponding contralateral areas; the
largest reduction in mineral content (45%) was observed
in the proximal third. McCarthy et al. [33] analysed
two regions and, three years after the operation,
showed: (a) a 40% mineral loss in the region containing
the lesser trochanter, and (b) a 28 % loss in the distal
region. More than 7 years after the operation, the losses
were respectively 40% and 49%. Kiratli et al. [26)
studied four ROis one year after the operation, and
found that the greatest mineral loss was in the region of
the lesser trochanter (32.6%) and in the regain immediately below it (30.3 %). Trevisan et al. [40] studied
seven peri prosthetic regions and compared them with the
contralateral regions of the healthy femur; eighteen
months after the operation, they found the greatest
150
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way as to obtain two photon energy levels (one of 40,
and the other of 70 keV). Five days after the operation,
and after four months of treatment, each patient underwent three absorptiometric scans: (a) one of the entire
body; (b) one of the proximal femur on the operated
side; and (c) one of the proximal femur on the contralateral side. Of the total body scans, the following
absorptiometric analyses were considered: (a) the total
skeleton; (b) the operated limb; and (c) the non-operated
limb. For the total body and the individual anatomical
regions evaluated, absorptiometry provided: (a) the
values of bone mineral content in grams (BMC); and (b)
the values of bone mineral density in g/cm2 (BMD).
The "in vivo" precision, calculated as the coefficient of
variation (CV%), was less than 1% for total body BMD
[35] and less than 1 % for the BMD of operated and
non-operated lower limbs.
For the post-operative comparison, four ROis at the
upper end of the femoral diaphysis were identified for
both the operated and the contralateral sides. These
regions, indicated by the numbers 1, 2, 3, and 4 in
Figure 1 were: (a) region 1, defmed as being "of the
lesser trochanter", wa5 5-10 mm wide and 20-30 mm
long; (b) region 2, immediately below region 1 (in the
medial femoral diaphysis), was 5-10 mm wide and 20-30
mm long; (c) region 3, defmed as being "of the greater
trochanter", was 5-10 mm wide and 25-35 mm long; and
(d) region 4, immediately below region 3 (in the lateral
femoral diaphysis) was 5-10 mm wide and 20-30 mm
long. The reproducibility of the measurements (CV%)
for each periprosthetic region was calculated in five subjects by scanning the prosthesis and the contralateral
femurs twice on the same day, with the patients being
repositioned between scans. The CV% was between
2.09% and 4.89% for the limb with the prosthesis, and
between 1.26% and 3% for the opposite limb. In each
individual case, a comparison was made between the
ROis of the operated femur and those of the opposite
femur.
Before the operation, and on a monthly basis after
the operation, the following parameters were measured
in all of the patients: plasma calcium (using atomic absorption spectrophotometry; Perkin-Elmer model 2280),
plasma phosphate and serum alkaline phosphatase (using
standard methods) The last check was made four months
after treatment.

reduction in BMD in the proximal and medial region (Z
score: approximately 1.8) and in the greater trochanter
(Z score: approximately 1.4).
At physiological doses of 1 p.g/day, synthetic
1,25(0H)2vitD3 (calcitriol): (a) normalizes the intestinal
absorption of calcium in patients with postmenopausal
osteoporosis [4, 9]; (b) eliminates bone mineral losses
[9, 10]; (c) reduces the incidence of fractures [9, 10, 11,
29]; (d) leads to an increase in osteocalcin [7], an index
of osteoblastic activity; and (e) has no toxic side effects
provided patients are not given calcium supplementation
[9].
The dual aims of this study were: (a) to measure the
BMD in the total body, in the operated limb, in the contralaterallimb, and in four peri prosthetic ROis; and (b)
to evaluate the efficacy of 1,25(0H)2vitD3 on bone loss
in the same districts at the time of a prosthesis implantation and four months later. Our study differed from
previous studies in that it evaluated bone mineral measurements immediately after the implantation of the hip
prosthesis, as well as the effect of four months of calcitriol treatment.

Material and Methods
Patients
Fourteen subjects were studied: four males (aged
58-80 years), and ten females (aged 61-90 years). Nine
of the patients (3 men and 6 women) underwent hip implantation as a result of fractures of minimal cause in
senile or postmenopausal osteoporosis; the remaining
five (1 man and 4 women) underwent total hip replacement because of coxarthrosis. Positive diagnoses were
made on the basis of the patients' histories (fractures,
pain, spine deformities), X-rays (demineralization, fractures), densitometry of the entire body and the femoral
area, laboratory data (plasma calcium, phosphate and alkaline phosphatase levels; 24 hour urinary calcium,
phosphate and hydroxyproline excretion). Patients with
secondary osteoporosis were excluded. A titanium
Omnifit prosthesis (Osteonics) with a hydroxyapatite
coating was used in all of the patients.
Of the 14 patients seven were treated with calcitriol
(1 p.g/day), without any calcium supplementation, from
the fifth day following the operation, whereas seven
others received two inert placebo tablets per day. This
was a double blind study, with the patients being randomly allocated to the two groups. All of the patients
gave their informed consent.

Statistical evaluations
The densitometric data were expressed as means ( ±
standard deviation, SD) and per cent variations. The
Student's t-test for unpaired data was used to evaluate
the significance of the difference between the mean
values and the percentage variations of the two treatment
groups, and of the prosthesis and contralateral femur.

Methods
The densitometric investigations were performed by
means of Lunar DPX equipment, using a constant potential X-ray source coupled to a "K-edge" filter in such a
151
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Table 1. Mean BMD values(± SD) and per cent variations of the total body, the entire prosthetic leg and the entire
opposite leg, before and after four months of treatment with placebo or calcitriol.
Placebo Group (BMD g/cm2)

Calcitriol Group (BMD g/cm2)

Baseline

Final

% var

p

Baseline

Final

% var

p

Total body

0.942
(0.132)

0.930
(0.141)

-1.38
(2.143)

n s.

0.920
(0.082)

0.922
(0.086)

0.176
(1.374)

n.s.

Prosthesis leg

0 960
(0.156)

0.901
(0.176)

-6.486
(5.214)

0.918
(0.124)

0.883
(0.124)

-3.601
(6.385)

n.s.

Opposite leg

0.931
(0.243)

0.922
(0.252)

-1.220
(1 931)

0.972
(0.183)

0.962
(0.175)

-0.921
(1.281)

n.s.

<

0.05

n.s.

Table 2. Mean BMD values(± SD) in the four regions of interest of the operated and non-operated femur, before
and after four months of treatment with placebo or calcitriol.

Regions
of
Interest

Calcitriol Group (BMD g/cm2)

Placebo Group (BMD g/cm2)

------------------------------------------p

------------------------------------Baseline

Final

p

0.05

1.467 ± 0.460

1.311 ± 0.467

n.s.

0.05

0.958 ± 0.335

0.947 ± 0.371

n.s.

0.05

0.668 ± 0.311

0.492 ± 0.301

n.s.

n.s.

1.361 ± 0.378

0.943 ± 0.218

1.349 ± 0.668

n.s.

1.456 ± 0.407

1.509 ± 0.381

n.s.

1.421 ± 0. 792

1.420 ± 0.852

n.s.

1.152 ± 0.244

1.252 ± 0.298

n.s.

3

0. 754 ± 0.456

0. 712 ± 0.508

n.s.

0.705 ± 0.305

0.799 ± 0.274

n.s.

4

1.193 ± 0.551

1.146 ± 0.576

n.s.

1.518 ± 0.453

1.517 ± 0.355

n.s.

Baseline

Final

1

1.353 ± 0.538

1.043 ± 0.652

2

1.401 ± 0.701

1.180 ± 0.747

3

0.766 ± 0.276

0.535 ± 0.423

4

1.164 ± 0.332

0.934 ± 0.467

1

1.480 ± 0.661

2

Prosthesis side

<
<
<

<

0.05

Opposite side

The significance of the mean values before and after
treatment was evaluated using the t-test for paired data.

Table 2 shows the mean BMD values in the four
ROis in the operated and opposite limbs, before and
after placebo or calcitriol treatment. After four months
of placebo therapy, the BMD values in regions 1, 2 and
3 were significantly lower in the prosthesis limb, but
there was no significant reduction in the opposite limb.
However, after four months of calcitriol treatment, the
BMD values in regions 1, 2 and 3 of the operated limb
were not significantly lower, but those in region 4 had
significantly decreased. In the opposite limb, the mean
values in the same regions had increased, although not
significantly so.

Results
Table 1 shows the mean BMD values and % variations for the entire body, the prosthesis limb and the opposite limb, before and after treatment with placebo or
calcitriol. The BMD values in the operated limb were
significantly lower after four months of placebo treatment (0.960 versus 0.901; p < 0.05; -6.1 %), but the
reduction after calcitriol treatment was not significant
(0.918 versus 0.883; p: not significant, n.s.; -3.8%).
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Figure 2. Percentage variations(± SD) in BMD in the four regions of interest of the operated and contralateral femur
after four months of treatment with placebo or calcitriol.

Figure 2 shows the percentage variations in the
BMD of the four ROis, before and after placebo or calcitriol therapy. In the operated limb, the percentage decrease in BMD after calcitriol therapy was lower than in
the subjects treated with placebo, although the differences between the percentages did not reach statistical
significance. In the non-operated limb, there was a decrease in BMD in the placebo group and an increase in
the calcitriol group. The difference between the percentages were not significant in the placebo group, but they
were in regions 1 and 3 of the group treated with calcitriol. The plasma calcium and phosphate levels, as well
as the serum alkaline phosphatase values, were normal
in all patients before surgery, and did not change after
treatment with either calcitriol or placebo.

increase in bone fragility and greater susceptibility to
fractures. Total body absorptiometry is a very good
method for measuring bone mass in osteoporosis, and it
also allows monitoring in both non-treated and drugtreated patients [32, 35].
In previous studies involving osteoporotic patients,
we have shown the long-term effects of calcitriol in
eliminating bone losses throughout the entire body [9,
10, 11]. Although a period of four months is usually
considered to be insufficient to reveal significant variations in BMD, regional analysis of the entire operated
limb and the entire opposite limb in the patients participating in the present study showed: (a) a significant reduction in the BMD of regions 1,2 and 3 in the prosthesis limb in the placebo group; (b) no significant reduction in the patients treated with calcitriol in the same regions, but a significant decrease in region 4. A study of
the mineralization of the peri prosthetic ROis showed the
presence of clear demineralization around the prosthesis.
The results reported by other authors vary according
to the time of observation (from one to seven or more

Discussion
Osteoporosis is a reduction in bone mass with normal mineralization of the bone matrix and a microarchitectural deterioration in bone tissue, with a consequent
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although its real physiopathological significance is not
known, seems to be important in the processes of bone
matrix calcification.
Given the short duration of the study, the considerable reduction in BMD found around the implants may
partially reflect an increase in bone remodelling in these
areas. Newly deposited bone is less mineralized and
thus has lower BMD values than old bone. Therefore,
over the short 4 month study period, this increase in
bone remodelling is not necessarily the same as periprosthetic bone resorption or bone loss. It is known that
bone resorption decreases during chronic calcitriol treatment, and so the positive effects of calcitriol treatment
on bone mass may be partly due to the filling in of the
remodelling space. As this effect would be more pronounced with a shorter study period, the results of this
short-term study involving only a few patients require
confirmation by a longer study involving a larger number of patients.

years after the operation), the analytical method (the
choice of the ROis) and, above all, the reference region
used to calculate the percentage variations (for example,
Engh et al. [20], McCarthy et al. [33] and Trevisan et
al. [40] used the ROis of the contralateral femur, whereas Kilgus et al. [25] used a femoral region below the
prosthesis.
Our study was based on an early evaluation (4
months post-surgery), and a simultaneous comparison
with the ROis of the contralateral limb, as well as a
comparison over time of the periprosthetic regions of the
same limb (making it similar to that of Kiratli et al.
[26]). The observed demineralization was: (a) greater
than the error of reproducibility, and is therefore not
attributable to that [26, 37] (Fig.2); (b) greater in the
more proximal ROis (Fig. 2), in accordance with the
fmdings of other authors [20, 25, 26, 33, 40]; and (c)
present in the corresponding ROis in the contralateral
femur, although to a lesser extent (Fig. 2). Aside from
the operation itself, it is obvious that all patients are
subject to general factors which lead to a worsening in
post-operative bone demineralization: in particular, the
immobilization (first absolute and then partial) that
negatively affects the maintenance of lower limb bone
mass during the four months immediately following the
operation.
It has been shown that long-term treatment with calcitriol (1 1-'g/day) has a beneficial effect in postmenopausal osteoporosis [5, 6, 8, 24, 17, 21, 22, 29, 30,
39]. In terms of total body absorptiometry, this treatment is capable of countering the progressive decrease
in bone mineral density, which is well known in osteoporotic women who are not appropriately treated. It is
clear that calcitriol treatment was expected to be equally
efficacious in the patients participating in the present
study, and this was confirmed by the increased densitometric values in the ROis of the non-operated limb, as
well as by the lower bone loss observed in the ROis of
the operated limb (Fig. 2).
Osteoblasts produce both bone collagen, the most
important component of the organic bone matrix, and
osteocalcin, or Bone G 1a Protein, which is quantitatively
the second largest protein component of the skeleton. It
is well known that 1,25(0H)2vitD is indispensable for
the production of osteocalcin by osteoblasts, and it has
been shown that calcitriolleads to a systemic increase in
plasma osteocalcin [7]. Recent studies [28] seem to
show that, in comparison with control subjects, there is
a reduction in 1,25(0H)2vitD in the bone tissue of osteoporotic patients with hip fracture. The use of calcitriol in postmenopausal osteoporosis may achieve two
goals: (a) that of normalizing intestinal calcium absorption, and thus blocking progressive bone loss; and (b)
that of increasing the production of osteocalcin which,
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Reviewer V: Could not the difference in BMD baseline
values between groups be a cause of statistical difference
between treated and control groups?
Authors: The number of patients in the present paper
is too few for a meaningful statistical analysis. Nevertheless, the differences of the results in placebo group
versus the calcitriol group was significant when the
mean baseline values were either higher or lower in the
single regions of interest. For example, for region 1:
1.353 versus 1.043 and 1.467 versus 1.311; and for
region 2: 1.401 versus 1.180 and 0.958 versus 0.947.

R.G. Erben: With a patient number of 7 per group,
would a non-parametric test not be more appropriate for
statistical evaluation?
Authors: Non-parametric text could be more appropriate for statistical evaluation though the resulting outcome
will be substantially similar.
W.S.S. Jee: Could you speculate why region 4 in the
calcitriol group showed a decrease in BMD?
H.U. Bryant: In region 4, there seems to be a significant decrease in BMD in the calcitriol group but not so
in the placebo group. This data would seem to go
against the hypothesis of the authors and is not consistent with the results from the other sites. Is this the
result of a redistribution phenomenon?
Authors: We do not know why region 4 showed a decrease in BMD in the calcitriol group. As the study is
continuing and a new steady state is at one year of
treatment, it is possible that this decrease in region 4
will not persist.

R.G. Erben: In the early phase of calcitriol treatment,
serum and urinary calcium levels should be measured
more frequently in order to exclude development of
hypercalcemialhypercalcuria. Do you have data on
calcium excretion, which is the most sensitive marker
for calcitriol toxicity?
Authors: During the early phase of calcitriol treatment,
we usually measure bone metabolism parameters on a
monthly base.
W.S.S. Jee: Do you have any histological material that
would clarify how this those of calcitriol is acting on the
tissue level?
Authors: We do not have any histological data that
would clarify how calcitriol acts at the tissue level.
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